{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:14:38Z","timestamp":1773436478035,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title>Study Objective<\/jats:title>\n                    <jats:p>\n                      The extended\u2010release (\n                      <jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\n                      ) form of venlafaxine is preferred because of improved patient adherence, but the immediate\u2010release (IR) form is frequently used after Roux\u2010en\u2010Y gastric bypass (\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      ) surgery because of concerns for malabsorption. The objective of this study was to determine whether a statistically significant and predictable change in the bioavailability of venlafaxine\n                      <jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\n                      capsules occurs after\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective nonblinded single\u2010dose pharmacokinetic study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Clinical research unit at a large tertiary care medical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>\n                      Ten adult pre\u2013bariatric surgery patients who met the criteria for noncomplicated\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      were enrolled and served as their own controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>\n                      Patients were administered one venlafaxine\n                      <jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\n                      75\u2010mg capsule at two visits\u2014the first visit at least 1\u00a0week before undergoing\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      and the second visit 3\u20134\u00a0months after\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      . Blood samples were collected at predetermined intervals over 48\u00a0hours after each dose, and the pharmacokinetics of venlafaxine were measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>\n                      Plasma levels of venlafaxine and its primary metabolite,\n                      <jats:italic>O<\/jats:italic>\n                      \u2010desmethylvenlafaxine (\n                      <jats:styled-content style=\"fixed-case\">ODV<\/jats:styled-content>\n                      ), were compared at baseline and 3\u20134\u00a0months after\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      . The areas under the serum concentration\u2013time curves from 0\u201324\u00a0hours (\n                      <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                      <jats:sub>0\u201324<\/jats:sub>\n                      ) for venlafaxine (mean\u00a0\u00b1\u00a0\n                      <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>\n                      734\u00a0\u00b1\u00a0602 vs 630\u00a0\u00b1\u00a0553\u00a0ng\u00b7hr\/ml, p=0.22) and\n                      <jats:styled-content style=\"fixed-case\">ODV<\/jats:styled-content>\n                      (mean\u00a0\u00b1\u00a0\n                      <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>\n                      894\u00a0\u00b1\u00a0899 vs 1083 \u00b1\u00a0972\u00a0ng\u00b7hr\/ml, p=0.07) were similar before and after\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      . Using a bioequivalence approach, differences in pre\u2010\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      and post\u2010\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      values of\n                      <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                      <jats:sub>0\u201324<\/jats:sub>\n                      , peak serum concentration, and time to peak serum concentration were not statistically significant for either venlafaxine or ODV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study suggests that\n                      <jats:styled-content style=\"fixed-case\">RYGB<\/jats:styled-content>\n                      does not significantly alter the amount of venlafaxine or its active metabolite,\n                      <jats:styled-content style=\"fixed-case\">ODV<\/jats:styled-content>\n                      , absorbed from a venlafaxine\n                      <jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\n                      capsule or the time over which it is absorbed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.2022","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T05:12:39Z","timestamp":1503897159000},"page":"1374-1382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of Bioavailability of Single\u2010Dose Extended\u2010Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery"],"prefix":"10.1002","volume":"37","author":[{"given":"Carrie A.","family":"Krieger","sequence":"first","affiliation":[{"name":"Pharmacy Services Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie L.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Pharmacy Services Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[{"name":"Division of Oncology Research Mayo Clinic Rochester Minnesota"},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loralie J.","family":"Langman","sequence":"additional","affiliation":[{"name":"Division of Clinical Biochemistry and Immunology Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen B.","family":"Grothe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A.","family":"Dierkhising","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-009-0014-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-009-9960-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-011-0517-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1381\/096089297765555197"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-014-1262-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1381\/0960892042386922"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1877-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.3.250"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp151062"},{"key":"e_1_2_7_11_1","unstructured":"PL Detail\u2010Document Bariatric Surgery and Medication Use. Pharmacist's Letter\/Prescriber's Letter. December 2013."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060033"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61176-2"},{"key":"e_1_2_7_14_1","unstructured":"Product monograph.GD\u2010venlafaxine XR capsules. Updated November 26 2013. Available fromhttp:\/\/www.pfizer.ca\/sites\/g\/files\/g10017036\/f\/201410\/gd-venlafaxine-non-annotated-pm-169286-E.pdf. Accessed December 12 2016."},{"key":"e_1_2_7_15_1","unstructured":"Guidance for industry: statistical approaches to establishing bioequivalence [Internet] 2001.Rockville MD:US Department of Health and Human Services. Available fromhttp:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm070244.pdf. Accessed December 12 2016."},{"key":"e_1_2_7_16_1","unstructured":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations [Internet] 2003.Rockville MD:US Department of Health and Human Services. Available fromhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3995B1_07_GFI-BioAvail-BioEquiv.pdf. Accessed December 12 2016."},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","unstructured":"C Krieger K Cedermark M Sarr 2013","DOI":"10.1063\/pt.4.2536"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100630"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkj067"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02389.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00614.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11050719"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2010.12.003"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182905ffb"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:50:54Z","timestamp":1761065454000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/phar.2022"],"URL":"https:\/\/doi.org\/10.1002\/phar.2022","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]},"assertion":[{"value":"2017-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}